Metoclopramide-Induced Neuroleptic Malignant Syndrome: A Review Study

Ghafour, Ideh; Elyasi, Forouzan

doi:10.5812/ijpbs.100888

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a rare, serious, and life‐threatening reaction, neuroleptic malignant syndrome (NMS) has been presented among the adverse effects of taking dopaminergic drugs, including typical/atypical antipsychotics, 1 metoclopramides, 2 and anti‐Parkinson's ones. This health condition is normally distinguished by rigidity, tremor, fever, overactive, or unstable sympathetic nervous system, altered mental status (AMS), leukocytosis, and the elevated level of creatine phosphokinase (CPK) 3 .…”

Section: Introductionmentioning

confidence: 99%

The management challenges of a case with Flupentixol‐induced neuroleptic malignant syndrome

Elyasi

Sadati

Heydari

2022

Neuropsychopharm Rep

Self Cite

View full text Add to dashboard Cite

Background Neuroleptic malignant syndrome (NMS) is a rare and life‐threatening reaction. The incidence rate of NMS has dropped because of the higher use of atypical antipsychotics, compared with the typical ones. The mortality rate in patients taking injectable antipsychotics has been also by 38%. Aim Here, a case developing the NMS symptoms following Flupentixol (FPX) use was reported. Case presentation The patient was a 46‐year‐old man with the history of schizoaffective disorder (SAD) and recently on six‐weekly doses of long‐acting (LA) typical antipsychotic drugs. He was referred with a fever, sweating, a food intolerance, mutism, and disorientation in 2019. He was presented with generalized rigidity, negativism, and neck stiffness. The patient's initial creatine phosphokinase (CPK) level was 1476 IU/L, which gradually elevated to 3997 IU/L on Day 26. NMS was further diagnosed, in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) criteria, and the score 9+ in the Naranjo Algorithm as the adverse drug reaction probability scale. Afterward, the patient was treated with bromocriptine at a dose of 5 mg 3 times a day, which progressively reached a maximum of 50 mg. He experienced sepsis and resistant respiratory infection several times. The case was finally discharged after 66 days of hospitalization, with a high level of consciousness, but limited verbal communication, in a fever‐free condition with the oral administration of bromocriptine and lorazepam. Conclusion In conclusion, there were suggestions for the management challenges of NMS in patients receiving LA injectable antipsychotic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

The management challenges of a case with Flupentixol‐induced neuroleptic malignant syndrome

Elyasi

Sadati

Heydari

2022

Neuropsychopharm Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder—A case report

Sadati,

Elyasi,

Shyasi

et al. 2024

Neuropsychopharm Rep

View full text Add to dashboard Cite

BackgroundNeuroleptic malignant syndrome (NMS) is a rare and potentially life‐threatening condition that may arise at any point during treatment and is often associated with adverse reactions to dopamine‐blocking agents. This syndrome is normally characterized by features such as muscle rigidity, alteration in consciousness, autonomic instability, and leukocytosis.AimThe aim of this study is to investigate a borderline intellectual functioning (BIF) case in which NMS with insidious disease progression and long prodromal symptoms was developed.Case PresentationThe investigated patient was a 38‐year‐old female diagnosed with bipolar disorder and a variety of corresponding disorders. The patient exhibited gastrointestinal symptoms and restlessness in the weeks leading up to the study, subsequent to the administration of elevated doses of haloperidol, risperidone, and lithium. In addition, she was hospitalized for restlessness and aggressiveness in the summer of 2023. Furthermore, due to her chief complaint, she received parenteral haloperidol twice in the emergency room, subsequently experiencing fever, altered consciousness, generalized rigidity, and dysphagia. Moreover, the patient's initial creatine phosphokinase (CPK) level was 2550 IU/L, and she was hospitalized in an intensive care unit with the diagnosis of NMS for 8 days.ConclusionsThis case study highlights the necessity of being attentive about prodromal symptoms of NMS and emergent interventions.

show abstract

Neuroleptic malignant syndrome in puerperal women

Muniandy,

Khalid,

Hamzah

et al. 2024

Journal of Emergency Medicine Case Reports

View full text Add to dashboard Cite

Introduction Neuroleptic malignant syndrome is an rare event, even more so among patient from puerperal period. The incidence risk is of 0.11%. It is often occurs when a patient is prescribed on antipsychotic for long duration of time. Case Report We report a case of a female patient, two weeks in post natal period presented with altered behaviour at home. She has prior admission being treated for post partum psychosis with anti psychotic. However antipschotic was withheld as she developed extrapyramidal symptoms while in ward. At home, she developed fever, altered sensorium and fitting-like-episode. On arrival patient was unresponsive and with features of impaired airway patency. Her had unstable vital sign with elevated blood pressure, heart rate and temperature. Brain imagine came back normal, excluding brain pathology. She was diagnosed as neuroleptic malignant syndrome as fulfilled features of elevated creatine kinase. She was treated symptomatic by providing first aid to reduce temperature and started on benzodiazepines. She was subsequently admitted to intensive ward and responded well to treatment Conclusion Physician must be familiar and have high index of suspicious to identify and treat neuroleptic malignant syndrome. Without prompt treatment, it is highly fatal.

show abstract

Metoclopramide-Induced Neuroleptic Malignant Syndrome: A Review Study

Cited by 3 publications

References 31 publications

The management challenges of a case with Flupentixol‐induced neuroleptic malignant syndrome

The management challenges of a case with Flupentixol‐induced neuroleptic malignant syndrome

Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder—A case report

Neuroleptic malignant syndrome in puerperal women

Contact Info

Product

Resources

About